Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Hisamitsu’s Allergic Rhinitis Drug Delivers Positive PIII Data
July 27, 2016
- Astellas Kicks Off Japan PIII for Renal Anemia Drug Roxadustat
July 27, 2016
- Hisamitsu’s US Unit Noven Transfers Rights to 2 Products to Sebela
July 27, 2016
- Luvox/Depromel Filed for Pediatric Obsessive-Compulsive Disorder in Japan: AbbVie, Meiji
July 26, 2016
- Asahi Kasei Pharma Seeks Nod for Longer Treatment Period for Teribone
July 25, 2016
- Fujifilm “Considering” Acquisition of Takeda’s Chemical Unit: Official
July 22, 2016
- PD-L1 Antibody Atezolizumab in Japan PIII for 7 Indications: Chugai
July 22, 2016
- Chugai Scores Solid Half-Year Sales on Meds for Cancer, Bone and Joint Disease
July 22, 2016
- Kyowa Kirin Ups January-June Earnings Guidance
July 22, 2016
- Chugai Picks Galderma as Global Partner for Antibody Atopic Dermatitis Drug
July 22, 2016
- Maruho, Galderma Give Update on Their Comprehensive Collaboration
July 21, 2016
- Hiroki Kitamura Picked as New Yoshindo President
July 21, 2016
- 38% of Complete Response Patients Remained in Remission for 5-Plus Years: Adcetris PII
July 20, 2016
- US FDA OKs Once-Daily Belviq: Eisai
July 20, 2016
- FDA, EMA Accept Opdivo Filing for Head and Neck Cancer
July 20, 2016
- Bayer, Taisho Join Hands on Switch OTC Version of Claritin
July 19, 2016
- Daiichi Sankyo to Commercialize Amgen’s 9 Investigational Biosimilars Including Adalimumab in Japan
July 15, 2016
- AnGes MG, Osaka Univ. Team Up for Joint Research on Novel Drug Delivery System
July 15, 2016
- Takeda Launches Awareness Campaign for Inflammatory Bowel Disease in Europe, US
July 14, 2016
- Not Much Difference in Efficacy, Safety between 2 PCSK9 Inhibitors: Dr Teramoto of Teikyo University
July 14, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…